Two-year results of a randomised double-blinded trial evaluating silymarin for chronic hepatitis C.
Strickland
G T
GT
Tanamly
M D
MD
Tadros
F
F
Labeeb
S
S
Makld
H
H
Nessim
D
D
Mikhail
N
N
Magder
L S
LS
Afdhal
N H
NH
Medhat
A
A
Abdel-Hamid
M
M
D000410:Alanine Transaminase / Q000097:blood; D000914:Antibodies, Viral / Q000032:analysis; D005500:Follow-Up Studies; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D020944:Silybum marianum; D020011:Protective Agents / Q000627:therapeutic use*; D012367:RNA, Viral / Q000032:analysis; D016032:Randomized Controlled Trials as Topic; D012838:Silymarin / Q000627:therapeutic use*; D016896:Treatment Outcome
D000914:Antibodies, Viral; D020011:Protective Agents; D012367:RNA, Viral; D012838:Silymarin; D000410:Alanine Transaminase